DDX53 and metastasis: As observed in CT26-FL3 liver metastasis, KPC liver metastasis was refractory to PD-L1 blockade therapy, while the combination of pRLN and pPD-L1 trap efficiently reduced the metastatic burden (Fig. 6a−c).